ArticleActive
Response to Comments: MolDX: Inivata, InVisionFirst, Liquid Biopsy for Patients with Lung Cancer
A56374
Effective: March 28, 2019
Updated: December 31, 2025
Policy Summary
This document is an administrative response to comments concerning the MolDX Inivata InVisionFirst liquid biopsy policy for lung cancer. It records the comment period (2018-11-15 to 2018-12-29), notice period (2019-03-28 to 2019-05-12), and that the LCD became final on 2019-05-13; it does not include clinical coverage criteria or requirements.
Coverage Criteria Preview
Key requirements from the full policy
"Administrative timeline: comment period 2018-11-15 to 2018-12-29; notice period 2019-03-28 to 2019-05-12; LCD becomes final 2019-05-13."
Sign up to see full coverage criteria, indications, and limitations.